MCID: DDN023
MIFTS: 38

Duodenal Benign Neoplasm

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Duodenal Benign Neoplasm

MalaCards integrated aliases for Duodenal Benign Neoplasm:

Name: Duodenal Benign Neoplasm 12 15 17
Neoplasm of the Duodenum 12
Neoplasm of Duodenum 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1737
MeSH 45 D004379
NCIt 51 C2995
UMLS 74 C0013291

Summaries for Duodenal Benign Neoplasm

MalaCards based summary : Duodenal Benign Neoplasm, also known as neoplasm of the duodenum, is related to duodenum cancer and duodenum adenoma. An important gene associated with Duodenal Benign Neoplasm is SST (Somatostatin), and among its related pathways/superpathways are Fc-GammaR Pathway and G12-G13 in Cellular Signaling. The drugs Celecoxib and Ursodeoxycholic acid have been mentioned in the context of this disorder. Affiliated tissues include lung, pancreas and thyroid, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

Related Diseases for Duodenal Benign Neoplasm

Diseases related to Duodenal Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 184)
# Related Disease Score Top Affiliating Genes
1 duodenum cancer 31.6 ENO2 HRAS KRAS NTHL1 SST
2 duodenum adenoma 11.3
3 pancreatic endocrine carcinoma 10.5 SST SYP
4 pituitary carcinoma 10.5 CHGA SST
5 glucagonoma 10.5 CHGA SST
6 pancreatic serous cystadenoma 10.5 CHGA SYP
7 conventional angiosarcoma 10.5 CHGA SYP
8 olfactory groove meningioma 10.5 CHGA SYP
9 panophthalmitis 10.5 CD79A SYP
10 ureter small cell carcinoma 10.5 CHGA SYP
11 melanotic neuroectodermal tumor 10.5 ENO2 SYP
12 cerebral ventricle cancer 10.4 ENO2 SYP
13 cerebral neuroblastoma 10.4 ENO2 SYP
14 extraosseous chondrosarcoma 10.4 ENO2 SYP
15 subependymal glioma 10.4 ENO2 SYP
16 benign ependymoma 10.4 ENO2 SYP
17 pineal gland cancer 10.4 ENO2 SYP
18 malignant teratoma 10.4 ENO2 SYP
19 endometrial small cell carcinoma 10.4 ENO2 SYP
20 astroblastoma 10.4 ENO2 SYP
21 acute thyroiditis 10.4 CHGA ENO2
22 mutyh-associated polyposis 10.4 APC KRAS
23 esophageal neuroendocrine tumor 10.4 CHGA SYP
24 ovarian large-cell neuroendocrine carcinoma 10.4 CHGA SYP
25 malignant glandular tumor of peripheral nerve sheath 10.4 SST SYP
26 acinar cell cystadenocarcinoma 10.4 CHGA SYP
27 peritoneal serous adenocarcinoma 10.4 CHGA SYP
28 cellular ependymoma 10.4 CHGA SYP
29 primary hepatic neuroendocrine carcinoma 10.4 CHGA SYP
30 carotid body cancer 10.4 ENO2 SYP
31 orbital plasma cell granuloma 10.4 MME SST
32 lung adenoid cystic carcinoma 10.4 HRAS KRAS
33 aggressive digital papillary adenocarcinoma 10.4 HRAS KRAS
34 appendix disease 10.4 HRAS KRAS
35 malignant sertoli cell tumor 10.4 ENO2 SYP
36 mongolian spot 10.4 ENO2 SST
37 intracranial primitive neuroectodermal tumor 10.4 CHGA ENO2
38 gastrointestinal neuroendocrine tumor 10.4 CHGA SST SYP
39 sinonasal undifferentiated carcinoma 10.3 ENO2 SYP
40 postcholecystectomy syndrome 10.3 GAST SST
41 binswanger's disease 10.3 CHGA SST SYP
42 retroperitoneal neuroblastoma 10.3 ENO2 SST
43 type c thymoma 10.3 CD5 SST
44 endocrine organ benign neoplasm 10.3 CHGA SST SYP
45 cutaneous ganglioneuroma 10.3 ENO2 SYP
46 rete testis adenocarcinoma 10.3 ENO2 MME
47 sigmoid neoplasm 10.3 HRAS KRAS
48 encapsulated thymoma 10.3 MME SST
49 hyperplastic polyposis syndrome 10.3 APC KRAS
50 papillary tumor of the pineal region 10.3 ENO2 SYP

Graphical network of the top 20 diseases related to Duodenal Benign Neoplasm:



Diseases related to Duodenal Benign Neoplasm

Symptoms & Phenotypes for Duodenal Benign Neoplasm

GenomeRNAi Phenotypes related to Duodenal Benign Neoplasm according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.1 CD5 CD79A CHGA GGT1 HRAS KRAS

MGI Mouse Phenotypes related to Duodenal Benign Neoplasm:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10 APC CD79A CHGA GAST GGT1 HRAS
2 behavior/neurological MP:0005386 9.97 APC ENO2 GGT1 HRAS KRAS NTHL1
3 nervous system MP:0003631 9.65 APC CD5 CD79A CHGA ENO2 HRAS
4 neoplasm MP:0002006 9.63 APC CD79A GAST HRAS KRAS NTHL1
5 no phenotypic analysis MP:0003012 9.17 CD5 CD79A CHGA HRAS KRAS NTS

Drugs & Therapeutics for Duodenal Benign Neoplasm

Drugs for Duodenal Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 2, Phase 3 169590-42-5 2662
2
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3 128-13-2 31401
3 Analgesics Phase 2, Phase 3
4 Gastrointestinal Agents Phase 2, Phase 3,Not Applicable
5 Peripheral Nervous System Agents Phase 2, Phase 3
6 Cholagogues and Choleretics Phase 2, Phase 3
7 Cyclooxygenase 2 Inhibitors Phase 2, Phase 3
8 Anti-Inflammatory Agents Phase 2, Phase 3
9 Analgesics, Non-Narcotic Phase 2, Phase 3
10 Cyclooxygenase Inhibitors Phase 2, Phase 3
11 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
12 Antirheumatic Agents Phase 2, Phase 3
13
leucovorin Approved Phase 2 58-05-9 143 6006
14
Irinotecan Approved, Investigational Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
15
Fluorouracil Approved Phase 2 51-21-8 3385
16
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
17
Pancrelipase Approved, Investigational Phase 2,Phase 1,Not Applicable 53608-75-6
18
nivolumab Approved Phase 2 946414-94-4
19
Ipilimumab Approved Phase 2 477202-00-9
20
Dalteparin Approved Phase 2 9005-49-6
21
Rivaroxaban Approved Phase 2 366789-02-8
22
Heparin Approved, Investigational Phase 2 9005-49-6 46507594 772
23
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
25
Serine Approved, Nutraceutical Phase 2 56-45-1 5951
26 Pancreatic Polypeptide Investigational Phase 2 59763-91-6
27 Trace Elements Phase 2
28 Vitamin B9 Phase 2
29 Antimetabolites, Antineoplastic Phase 2,Phase 1
30 Antidotes Phase 2
31 Antimetabolites Phase 2,Phase 1
32 Hormones Phase 2,Not Applicable
33 Calcium, Dietary Phase 2
34 Bone Density Conservation Agents Phase 2
35 Immunologic Factors Phase 2,Phase 1
36 Vitamin B Complex Phase 2
37 Immunosuppressive Agents Phase 2,Phase 1
38 pancreatin Phase 2,Phase 1,Not Applicable
39 Vitamins Phase 2
40 Folate Phase 2
41 Nutrients Phase 2
42 Micronutrients Phase 2
43 Topoisomerase Inhibitors Phase 2,Phase 1
44 topoisomerase I inhibitors Phase 2,Phase 1
45 Protective Agents Phase 2
46 Antibodies Phase 2
47 Immunoglobulins Phase 2
48 Antineoplastic Agents, Immunological Phase 2
49 Antibodies, Monoclonal Phase 2
50 Anticoagulants Phase 2

Interventional clinical trials:

(show all 38)
# Name Status NCT ID Phase Drugs
1 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
2 Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis Completed NCT00808743 Phase 2, Phase 3 Celecoxib;Ursodeoxycholic acid;Placebo
3 Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy Completed NCT01731821 Phase 3
4 Study of Gastroduodenal Metallic Stent vs Gastrojejunostomy Recruiting NCT02784470 Phase 3
5 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
6 A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers Recruiting NCT02923934 Phase 2 Ipilimumab;Nivolumab
7 A Randomized Phase II Study to Compare the Safety and Efficacy of Dalteparin vs. Rivaroxaban for Cancer-associated Venous Thromboembolism Recruiting NCT03139487 Phase 2 Rivaroxaban;Dalteparin
8 Comparing Endoscopic Based Stent Strategy Versus Bypass Surgery in Non-resectable Periampullary Cancer Withdrawn NCT00487851 Phase 2
9 Study of TCM Syndrome of Hepatocellular Carcinoma and Colorectal Cancer Based on System Science Unknown status NCT03189992 Phase 1 Bushen-Jianpi Dedoction;cinobufotalin injection
10 Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer Completed NCT00987766 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin
11 Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers Completed NCT00183846 Phase 1 irinotecan
12 A Study of Guselkumab in Participants With Familial Adenomatous Polyposis Recruiting NCT03649971 Phase 1 Guselkumab;Placebo
13 Proximal Roux-en-y Gastrojejunal Anastomosis on Delayed Gastric Emptying After Pylorus-resecting Pancreaticoduodenectomy Unknown status NCT02954302 Not Applicable
14 Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP) Unknown status NCT02656134
15 Comparing the Efficacy of Endoscopic FNA vs FNB in Diagnosing Solid Gastrointestinal Lesions Unknown status NCT01698190 Not Applicable
16 Evaluation of Isolated Roux-en-Y Reconstruction After Pancreaticoduodenectomy Unknown status NCT00915863 Not Applicable
17 Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders Unknown status NCT01438385
18 Duodenal Cancer - Retrospective Analysis Completed NCT01661049
19 A Pan-European Study on Minimally Invasive Versus Open Pancreatoduodenectomy in High-volume Centers Completed NCT03172572
20 Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy Completed NCT00639314 Not Applicable
21 Randomized Controlled Trial on Pancreatic Stent Tube in Pancreaticoduodenectomy Completed NCT00628186 Not Applicable
22 Postoperative Oral Nutritional Supplementation After Major Gastrointestinal Surgery Completed NCT01838109 Not Applicable
23 The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery Completed NCT02381249 Not Applicable Octreotide;Placebo
24 Colonization of Bile Ducts and Postoperative Infectious Complications of Pancreaticoduodenectomies Completed NCT03525067
25 Feasibility Study for Robotic Endomicroscopy to Better Define Resection Strategies (PERSEE) Completed NCT02312167 Not Applicable
26 Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality Completed NCT02378337
27 Endoscopic Evaluation of Duodenal Polyposis in Patients With Familial Adenomatous Polyposis (FAP) Recruiting NCT03346980
28 Enteral Nutrition After Pancreaticoduodenectomy Recruiting NCT03150615 Not Applicable
29 Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions Recruiting NCT01750619
30 Monitoring of patIents With Microdialysis Following Pancreaticoduodenectomy Recruiting NCT03631173 Not Applicable
31 Endoscopic Resection Multicenter Registry Recruiting NCT03065257
32 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
33 Pancreaticoduodenectomy With or Without Preoperative Hyperbaric Oxygen Therapy Enrolling by invitation NCT02575014 Not Applicable Preoperative hyperbaric oxygen
34 CryoBalloon Ablation for Treatment of Duodenal Adenomas Enrolling by invitation NCT03847636 Not Applicable
35 Magnetic Compressive Anastomosis for Biliojejunostomy and Pancreaticojejunostomy During Whipple's Procedure Not yet recruiting NCT03792048 Not Applicable
36 A Randomized Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy Terminated NCT00359320 Not Applicable
37 Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer Terminated NCT00899132
38 Use of the EnLightTM and LightPathTM Imaging Systems in Gastrointestinal Tumour Surgery Withdrawn NCT02446379 The marketed product 2-5 MBq/kg 18F-fluorodeoxyglucose

Search NIH Clinical Center for Duodenal Benign Neoplasm

Genetic Tests for Duodenal Benign Neoplasm

Anatomical Context for Duodenal Benign Neoplasm

MalaCards organs/tissues related to Duodenal Benign Neoplasm:

42
Lung, Pancreas, Thyroid, Liver, B Cells, Small Intestine, Pineal

Publications for Duodenal Benign Neoplasm

Variations for Duodenal Benign Neoplasm

Expression for Duodenal Benign Neoplasm

Search GEO for disease gene expression data for Duodenal Benign Neoplasm.

Pathways for Duodenal Benign Neoplasm

GO Terms for Duodenal Benign Neoplasm

Biological processes related to Duodenal Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 glutamate metabolic process GO:0006536 9.46 GGT1 GGT2
2 zymogen activation GO:0031638 9.43 GGT1 GGT2
3 cysteine biosynthetic process GO:0019344 9.4 GGT1 GGT2
4 response to isolation stress GO:0035900 9.37 HRAS KRAS
5 regulation of long-term neuronal synaptic plasticity GO:0048169 9.33 HRAS KRAS SYP
6 regulation of immune system process GO:0002682 9.32 GGT1 GGT2
7 peptide modification GO:0031179 9.26 GGT1 GGT2
8 glutathione catabolic process GO:0006751 9.13 GGT1 GGT2 GGTLC3
9 leukotriene D4 biosynthetic process GO:1901750 8.8 GGT1 GGT2 GGTLC3

Molecular functions related to Duodenal Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidyltransferase activity GO:0000048 8.96 GGT1 GGT2
2 glutathione hydrolase activity GO:0036374 8.8 GGT1 GGT2 GGTLC3

Sources for Duodenal Benign Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....